ArticleFrontiers in pharmacology2025

Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma.

Qi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.